Immunovant’s latest earnings call projected clear optimism, as management leaned into robust Phase II data for brepocitinib in cutaneous sarcoidosis and a deep pipeline of registrational trials.
I point the reborn Ram TRX at the next jump and mash the gas. The supercharger instantly drowns out the brapping bikes at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results